Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RPID Stock Forecast 2026-2027
$1.76
Current Price
$87.69M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RPID Price Targets
+354.5%
To High Target of $8.00
+297.7%
To Median Target of $7.00
+184.1%
To Low Target of $5.00
RPID Price Momentum
-11.6%
1 Week Change
-24.1%
1 Month Change
-50.4%
1 Year Change
-39.3%
Year-to-Date Change
-64.4%
From 52W High of $4.94
0.0%
From 52W Low of $1.76
📊 TOP ANALYST CALLS
Did RPID Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rapid Micro is one of their latest high-conviction picks.
Latest RPID Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, RPID has a bullish consensus with a median price target of $7.00 (ranging from $5.00 to $8.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.76, the median forecast implies a 297.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Paul Knight at Keybanc, suggesting a 184.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RPID Analyst Ratings
4
Buy
0
Hold
0
Sell
RPID Price Target Range
Low
$5.00
Average
$7.00
High
$8.00
Current: $1.76
Latest RPID Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RPID.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 29, 2026 | Keybanc | Paul Knight | Overweight | Maintains | $5.00 |
| May 22, 2026 | Lake Street | Thomas Flaten | Buy | Maintains | $7.00 |
| Jul 28, 2025 | Lake Street | Buy | Initiates | $N/A | |
| Feb 12, 2025 | Keybanc | Overweight | Initiates | $N/A | |
| Mar 7, 2023 | Morgan Stanley | Equal-Weight | Reiterates | $N/A | |
| Aug 16, 2022 | JP Morgan | Neutral | Downgrade | $N/A | |
| May 11, 2022 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Mar 7, 2022 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Feb 15, 2022 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Nov 15, 2021 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Aug 9, 2021 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Aug 9, 2021 | Morgan Stanley | Equal-Weight | Initiates | $N/A | |
| Aug 9, 2021 | Stifel | Buy | Initiates | $N/A | |
| Aug 9, 2021 | JP Morgan | Overweight | Initiates | $N/A |
Rapid Micro Biosystems, Inc. (RPID) Competitors
The following stocks are similar to Rapid Micro based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rapid Micro Biosystems, Inc. (RPID) Financial Data
Rapid Micro Biosystems, Inc. has a market capitalization of $87.69M with a P/E ratio of -1.7x. The company generates $34.38M in trailing twelve-month revenue with a -145.8% profit margin.
Revenue growth is +11.1% quarter-over-quarter, while maintaining an operating margin of -173.1% and return on equity of -116.7%.
Valuation Metrics
Market Cap
$87.69M
Enterprise Value
$86.79M
P/E Ratio
-1.7x
PEG Ratio
-0.1x
Price/Sales
2.7x
Growth & Margins
Revenue Growth (YoY)
+11.1%
Gross Margin
+4.6%
Operating Margin
-173.1%
Net Margin
-145.8%
EPS Growth
+11.1%
Financial Health
Cash/Price Ratio
+29.2%
Current Ratio
2.6x
Debt/Equity
116.2x
ROE
-116.7%
ROA
-41.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rapid Micro Biosystems, Inc. (RPID) Business Model
About Rapid Micro Biosystems, Inc.
What They Do
Provides automation solutions for microbial detection.
Business Model
The company generates revenue by offering advanced technological systems that enhance quality control in pharmaceutical manufacturing. By automating microbial detection, Rapid Micro Biosystems helps biopharmaceutical companies improve efficiency and ensure compliance with stringent safety regulations, thereby creating a vital service within the industry.
Additional Information
The company is positioned in a critical sector that emphasizes product integrity and patient safety, contributing to public health through innovative scientific solutions. Its focus on technological advancement in microbial quality control highlights its role as an essential partner for companies in the life sciences industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
171
CEO
Mr. Robert G. Spignesi Jr.
Country
United States
IPO Year
2021
Website
www.rapidmicrobio.comRapid Micro Biosystems, Inc. (RPID) Latest News & Analysis
Latest News
Quick Summary
Rapid Micro Biosystems granted 60,000 RSUs to a new employee on June 3, 2026, as part of its Inducement Plan, approved by independent directors per Nasdaq rules.
Why It Matters
The grant of 60,000 RSUs indicates confidence in attracting talent, which can enhance company performance and drive growth, potentially impacting stock value positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
26 days ago
Quick Summary
Bain Capital Life Sciences and Armistice Capital are investing $9.8 million in a company, with potential total funding of $32 million if warrants are exercised. Company directors and officers are also participating.
Why It Matters
The $9.8 million investment, potentially increasing to $32 million, signals strong confidence from Bain Capital and insiders, suggesting positive growth prospects for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapid Micro Biosystems (NASDAQ: RPID) reported Q1 2026 revenue growth, reaffirmed its full-year outlook, and emphasized improving gross margins as a key focus.
Why It Matters
Rapid Micro Biosystems' revenue growth and reaffirmed outlook indicate strong operational performance, suggesting potential for increased profitability and investor confidence in future earnings.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Rapid Micro Biosystems, Inc. (RPID) held its Q1 2026 earnings call, discussing financial results and company performance. Further details on earnings and future outlook were provided.
Why It Matters
The Q1 2026 earnings call provides insights into Rapid Micro Biosystems' financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) reported its Q1 financial results for 2026, focusing on automation solutions for healthcare product manufacturing and release.
Why It Matters
Rapid Micro Biosystems' Q1 financial results indicate its operational performance and growth potential, impacting stock valuation and investor sentiment in the life sciences sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapid Micro Biosystems, Inc. (RPID) reported a quarterly loss of $0.31 per share, exceeding the estimate of a $0.25 loss and up from a $0.26 loss per share a year earlier.
Why It Matters
Rapid Micro Biosystems' larger-than-expected quarterly loss may indicate worsening financial health, potentially impacting stock performance and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About RPID Stock
What is Rapid Micro Biosystems, Inc.'s (RPID) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Rapid Micro Biosystems, Inc. (RPID) has a median price target of $7.00. The highest price target is $8.00 and the lowest is $5.00.
Is RPID stock a good investment in 2026?
According to current analyst ratings, RPID has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RPID stock?
Wall Street analysts predict RPID stock could reach $7.00 in the next 12 months. This represents a 297.7% increase from the current price of $1.76. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rapid Micro Biosystems, Inc.'s business model?
The company generates revenue by offering advanced technological systems that enhance quality control in pharmaceutical manufacturing. By automating microbial detection, Rapid Micro Biosystems helps biopharmaceutical companies improve efficiency and ensure compliance with stringent safety regulations, thereby creating a vital service within the industry.
What is the highest forecasted price for RPID Rapid Micro Biosystems, Inc.?
The highest price target for RPID is $8.00 from at , which represents a 354.5% increase from the current price of $1.76.
What is the lowest forecasted price for RPID Rapid Micro Biosystems, Inc.?
The lowest price target for RPID is $5.00 from Paul Knight at Keybanc, which represents a 184.1% increase from the current price of $1.76.
What is the overall RPID consensus from analysts for Rapid Micro Biosystems, Inc.?
The overall analyst consensus for RPID is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are RPID stock price projections?
Stock price projections, including those for Rapid Micro Biosystems, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 10:42 AM UTC